Proven strategies to reduce cardiovascular mortality in hemodialysis patients

Blood Purification

Volumn 24, Issue 1, 2006, Pages 100-106

  Hampl, H ^a,c   Hennig, L ^a   Rosenberger, C ^a   Gogoll, L ^a   Riedel, E ^a   Scherhag, A ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Nierenzentrum ^*  (Germany)

Author keywords

Hemodialysis; Left ventricular hypertrophy; Optimized cardiac therapy; Total anemia correction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; METOPROLOL; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; SIMVASTATIN;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

AGED; ANEMIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; RENAL DIALYSIS; UREMIA;

EID: 29244442711     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089445     Document Type: Article

References (29)

1. Silberberg JS, Barre PE, Prichard PS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-290.
2. Foley NF, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre BE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995;5:2004-2031.
3. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
4. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Serial echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000;11:912-916.
5. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LF: Left ventricular mass monitoring in the follow-up of dialysis patients. Prognostic value of left ventricular hypertrophy progression. Kidney Int 2004;65:1492-1498.
6. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiagraphically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
7. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 2001;114:345-352.
8. Benjamin EJ, Levy D: Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 1999;317:168-175.
9. Devereux R, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:1325-1350.
10. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, Miller DH, Reis G, Aldermann AH, Laragh JH: Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984;4:1222-1230.
11. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme therapy in patients with end-stage renal disease and acute myocardial infarction. J Am Coll Cardiol 2003;42:209-210.
12. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA: Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001;37:484-489.
13. Griffith TF, Chua BSY, Allen AS, Klassen PS, Reddan DN, Szczech LA: Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2003;42:1260-1269.
14. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805.
15. Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abbott KC: Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003;41:1267-1277.
16. Amann K, Buzello M, Simonavicienc A, Miltenberger-Miltenyi G, Koch A, Nabokov A, Gross ML, Gless B, Mall G, Ritz E: Capillary/ myocyte mismatch in the heart in renal failure - A role for erythropoietin? Nephrol Dial Transplant 2000;15:964-969.
17. Hampl H: Hemodynamic state in severe chronic renal failure. Nephron 1985;39:102-111.
18. Hampl H, Hennig L, Rosenberger CH, Amirkhalily M, Gogoll L, Riedel E, Scherhag A: Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients. Am J Nephrol 2005;25:211-220.
19. Lehninger AL, Nelson DL, Cox MM: Prinzipien der Biochemie. Heidelberg, Spektrum, 1994, p 851.
20. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effects of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-1335.
21. US Renal Data System, USRDS 2002 annual data report: atlas end-stage renal disease in the United States. Bethesda, NIH, National Institute of Diabetes and Digestive and Kidney Disease, 2002.
22. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32 (suppl 3):112-119.
23. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884-890.
24. Schreiber BD: Congestive heart failure in patients with chronic kidney disease and on dialysis. Am J Med Sci 2003;325:179-193.
25. Vlahakos DV, Hahalis G, Vassilakos P, Marathias KP, Geroulanos S: Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol 1997;8:1764-1770.
26. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH: Sympethetic nerve activity in end-stage renal disease. Circulation 2002;106:1974-1979.
27. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal versus low treated hematocrit values in hemodialysis patients with cardiac disease with erythropoietin. N Engl J Med 1998;339:584-590.
28. Parfrey PS, Foley RN, Wittreich BH, Sullivan JD, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005;16:2180-2189.
29. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre BE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192.